Showing 311-320 of 353 grants
| Title | Institution | Researcher | Program | Duration | Total Award Amount |
|---|---|---|---|---|---|
| Promoting functional maturation of SC-derived beta-cells by novel Epigenetic regulators | University of Washington | Vincenzino Cirulli | Cures | 01-October-2024 to 30-September-2026 | $500.000,00 |
| METabolic MODulation to Enhance Insulin Sensitivity and Mitochondrial Function in Type 1 Diabetes (MetMod-T1D) | University of Washington | Petter Bjornstad | Improving Lives | 01-September-2025 to 31-August-2028 | $2.040.014,30 |
| Thermally responsive minimally invasive proangiogenic placeholder for cell transplantation for Type 1 Diabetes | University of Washington | Patrick Stayton | Cures | 01-November-2025 to 31-October-2028 | $894.965,96 |
| Randomized trial of semaglutide for diabetic kidney disease in type 1 diabetes | University of Washington | Ian De Boer | Improving Lives | 01-September-2023 to 31-March-2028 | $2.107.411,00 |
| ICAM-1 Knock Out Pluripotent Stem Cells for Hypoimmune Type 1 Diabetes Therapy | University of Wisconsin-Madison (Board of Regents University of Wisconsin System) | Matthew Brown | Cures | 01-April-2025 to 31-March-2027 | $699.998,53 |
| Stem Cell-derived Islet Vascularized Extracellular Matrix Organoids for Enhanced Transplantation Success | University of Wisconsin-Madison (Board of Regents University of Wisconsin System) | Jon Odorico | Cures | 01-January-2024 to 31-December-2026 | $1.394.960,67 |
| Process development for adipose tissue implantation of immune evasive ES-derived islet-like cells | University of Wisconsin-Madison (Board of Regents University of Wisconsin System) | Jacques Galipeau | Cures | 01-January-2026 to 31-December-2027 | $628.883,28 |
| Identifying the temporal functions of beta cell UPR in T1D | University of Wisconsin-Madison (Board of Regents University of Wisconsin System) | Feyza Engin | Cures | 01-February-2023 to 31-January-2028 | $750.000,00 |
| Single nucleus multiomics temporal profiling of islet immune cells in male and female NOD mice during UPR-deficiency-induced senescence | University of Wisconsin-Madison (Board of Regents University of Wisconsin System) | Feyza Engin | Cures | 01-February-2025 to 31-January-2028 | $750.000,00 |
| Modes of action of a beta cell targeted prodrug for preventing and treating type 1 diabetes | UT Southwestern | Wen-hong Li | Cures | 01-November-2025 to 31-October-2028 | $990.000,00 |